When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to ...

Chimeric antigen receptor (CAR) T cells targeting CD19 have ... in 62% of the patients (47% with grade 1 or 2), and immune effector-cell–associated neurotoxicity syndrome occurred in 14% ...

Beyond the Point: Learning From Outcomes After Inpatient Immune Checkpoint Inhibitor Therapy Chimeric antigen receptor T-cell (CAR-T ... risks of cytokine release syndrome (CRS) and immune effector ...

A key enzyme and its molecular pathway are critical to keeping certain immune cells active and away from "exhaustion," ...

This report describes a usually mild syndrome, dubbed LICATS, affecting about three-quarters of CAR T-cell recipients.

New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...

A key enzyme and its molecular pathway are critical to keeping activated CD8+ T cells active and away from “exhaustion”, ...

Shares of Portage Biotech climbed after the company reported confirmatory data for its PORT-7 treatment of mesothelioma, supporting plans for a human trial. The stock rose 21% to $10.23 Monday. Shares ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...

Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon ...

Such infections are initiated at mucosal surfaces, where there is a close association between polarized epithelial cells and immune effector cells ... transported across the mucosal barrier by FcRn, a ...